** Shares of healthcare products distributor Henry Schein HSIC.O rise ~4% to $71.94
** BofA Securities upgrades stock to "buy" from "underperform"; raises price objective to $84 from $69
** HSIC stands out as a "best-of-breed dental asset" with a proven ability to grow earnings at healthy rates, similar to its performance before COVID-19, brokerage says
** Company is well-positioned to gain share from both distributors and manufacturers due to its exposure to high-growth dental service organizations (DSO) customers and private label offerings - BofA Securities
** HSIC is positioned for long-term success with "best-in-class portfolio in dental", with above-market exposure to DSO customers - brokerage
** Six of 15 brokerages rate the stock "buy" or higher, 7 "hold" and 2 "sell"; median PT is $75 - data compiled by LSEG
** HSIC fell 8.6% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。